Erenapurstat · APX-3330, E-3330

What is Erenapurstat?

Erenapurstat is an orally bioavailable small molecule that selectively binds APE1/Ref-1 (APEX1) and blocks its redox activity, preventing the reduction and activation of transcription factors such as NF-kB, AP-1, STAT3 and HIF-1alpha, while leaving its DNA repair endonuclease function intact. It is studied in diabetic retinopathy and diabetic macular edema.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

APX-3330, E-3330

Drug type

Small molecule

Targets

apurinic/apyrimidinic endonuclease 1/redox effector factor-1 (APE1/Ref-1) (APEX1)

Mechanism

Inhibitor of apurinic/apyrimidinic endonuclease 1/redox effector factor-1 (APE1/Ref-1) (APEX1)

Pathways

NF-kB signaling, AP-1 signaling, STAT3 signaling, HIF-1alpha signaling, NRF2 signaling

Therapy area

Ophthalmology

Developer

Opus Genetics, Inc (IRD)

FDA status

Investigational, not approved in the US. Most advanced trial: Phase 2

UNII

11267UI968

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Diabetic Macular EdemaDiabetic RetinopathyNPDR - Non Proliferative Diabetic RetinopathyPDR - Proliferative Diabetic Retinopathy

More from Opus Genetics

Sources

• NCI Thesaurus
• ClinicalTrials.gov NCT04692688

Updated Oct 11, 2026. Something wrong or missing? Report it on the IRD page.